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Abstract
Background: To assess the results for local control (LC) and survival in patients with early-stage glottic cancer (GC)
who were treated by radiotherapy (RT) with or without chemotherapy.
Methods: Fifty-eight patients with T1-T2 squamous cell carcinoma of the glottis who were treated between 2001
and 2006 were analyzed retrospectively. Potential prognostic factors for LC were evaluated by univariate analysis.
Results: The 5-year LC rate in all patients was 84.3%. The overall 5-year LC rates for patients with T1a, Tb, and T2
GC were 85.9%, 83%, and 85%, respectively. Of the 58 patients, eight developed recurrent disease at the primary
site, and one had lymph node recurrences on the neck. In the final analysis, the total laryngectomy-free survival
rate was 93% at five years, and the ultimate LC rates for T1a, Tb, and T2 were 100%, 90.9%, and 95.2%, respectively.
In a univariate analysis of 55 patients, there was no statistical significance between the LC rate for RT alone and
that for chemoradiation. Only two patients died of laryngeal carcinoma, and one died of intercurrent disease. Fifty-
five patients were living disease-free at the end of the study period. The 5-year overall survival (OS) rate for all
patients was 88.1%, and the 5-year OS rates for T1a, Tb, and T2 were 91.6%, 77.8%, and 89.9%, respectively.
Conclusions: The retrospective analysis showed a high rate of LC and larynx preservation in patients with T1-T2
GC by means of RT with or without chemotherapy. There was, however, no statistical difference in LC rates for the
two types of therapy.
Background
Glottic carcinoma (GC), the most common laryngeal
cancer, and is usually detected early because of the
symptomatic occurrence of hoarse voice. The recom-
mended strategies for early GC with the intent of larynx
preservation are radiation therapy (RT), transoral laser
therapy, and partial laryngectomy [1,2].
RT is the preferred therapeutic method in early GC.
The advantages of RT in terms of preservation of the
structure and function of the larynx have been docu-
mented extensively, and RT currently is the initial treat-
ment of choice in most institutions, with surgery being
reserved as a salvage option for local failure. For T1 GC,
the LC rate for RT alone has been reported to be about
80-90% [3-8], whereas for T2 GC, the LC rate has been
about 65-80% [4,5,7,8]. Based on our previously reported
data for 1990-1997, the LC rate of T2 GC by RT alone
was 65% at our institute.
The purpose of this study was to review retrospec-
tively our experience in the treatment of T1 and T2 GC
through RT with or without chemotherapy from 2001
to 2006.
Methods
Patient characteristics
A retrospective review was performed of 58 patients
who had undergone radical RT with or without che-
motherapy to the larynx for Stage I-II GC (T1-T2, N0
according to the 2002 International Union Against Can-
cer classification system). Patients were treated at
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April 2006. All patients received RT as the first-choice
treatment. Patient inclusion criteria were a histologic
diagnosis of infiltrative squamous cell carcinoma and no
previous RT for head and neck neoplasms. Fifty-five
patients (95%) were male, and three (5%) were female.
The median age was 64 years (range, 44-92 years). The
initial examinations before the start of the treatment
included physical examination, blood count, biochemical
examination, electrocardiography, and staging proce-
dures including computed tomography (CT) scan of the
whole body and upper endoscopy. The presence of
human papillomavirus (HPV) was not examined. Table
1 contains a summary of the clinical characteristics of
the 58 patients who were included in the study.
Twenty-four patients had tumors classified as T1a, 13
had T1b tumors, and 21 patients T2 tumors. All
patients were followed for a median period of 48
months (range, 13-84 months) or until death.
Treatments detail
Radiotherapy
Table 2 contains a summary of the treatment courses of
the 58 patients. Thirty-nine patients were treated with
RT alone; 19 received RT and chemotherapy. Fifty-seven
patients were treated with parallel-opposed fields using
4-MV, and only one patient was treated using 6-MV.
Fifty-four patients received a continuous course of RT
with a once-daily fraction of 2 Gy, and four patients
were treated with a continuous course of RT delivered
twice a day to a total dose of 74 Gy to 82 Gy, with 1.2
Gy to 1.3 Gy per fraction. Wedge filters of 15 or 30
degrees were used to optimize the dose distribution to
achieve a homogeneity of ± 5%. The field size ranged
from 25 to 36 cm
2. No prophylactic neck irradiation
was performed in any of the cases. All patients were
immobilized using a thermoplastic mask during
treatment.
Chemotherapy
The various chemotherapy drugs and regimens used are
listed in Table 3. The chemotherapeutic regimen for five
patients given a high dose of CDDP/5-FU consisted of
continuous infusion of 5-FU at a dose of 700 mg/m
2/
day on days 1-4, combined with a 2-hr infusion of
CDDP at a dose of 70 mg/m
2/day on day 1. Low-dose
CDDP/5-FU was continuously administered to five
other patients via different routes through a catheter
placed in the central vein. The daily dose of 5-FU was
given at 200 mg/m
2, and that of CDDP was 4 mg/m
2.
CDDP and 5-FU were administered for 24 hr every day,
except Saturday and Sunday, from the day irradiation
was started. The regimen for four patients was a low
dose of CDDP alone, consisting of 60-min administra-
t i o no fC D D Pa tad o s eo f5m g / b o d ya f t e rR T .T h e
other regimens are listed in Table 3.
In three patients treated with chemoradiotherapy (two
cases) or RT alone (one case), tumor responses were
very poor. For these patients, treatments were discontin-
ued at 18 Gy, 36 Gy, and 52 Gy, and partial laryngec-
tomies were performed.
In our basic concept, the regimens of a low dose of
CDDP, Carboplatin, UFT, or a low dose of CDDP/5-FU
were mainly used for bulky T1 and T2 tumor, on the
other hand, the regimens of a high dose of CDDP or
alternative CDDP/5-FU were used for unfavorable T2
tumor (maybe, near T3).
Table 1 Patients characteristics
n percentage
Total no. of patients 58 100
Age median (range) 64 y.o. (44-92)
Male/Female 55/3 95/5
Performance status (ECOG)
0-1 56 96
22 4
Histology
squamous cell carcinoma 58 100
Stage
T1a 24 41
T1b 13 22
T2 21 36
Table 2 Radiation therapy
n percentage
Conventional 54 93
Dose range 18-82Gy Median 70Gy/35fx
AFX-CB 3 5
Dose range 60.8-76Gy Median 67Gy
Accelerated hyperfractionation 1 2
Dose range 60Gy Median 60Gy/40fx
AFX-CB: accelerated fractionation with concomitant boost
Table 3 Chemotherapy and these regimen
With chemotherapy Radiation alone total
n (%) n (%) n
T1a 1 (4) 23 (96) 24
T1b 4 (30) 9 (70) 13
T2 14 (67) 7 (33) 21
Regimen n (%)
Low dose CDDP 4 (21)
Low dose CDDP/5FU 5 (26)
High dose CDDP/5FU 5 (26)
Carboplatin 2 (10)
Alternative CDDP/5FU 2 (10)
UFT(oral antidrug) 1 (5)
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LC and total laryngectomy-free survival were assessed
from the beginning of RT until evidence of recurrence
or until laryngectomy. Survival curves were calculated
using the method of Kaplan and Meier, and log-rank
tests were used to define the statistical significance of
the observed differences in survival and LC based on
univariate analysis. The results were considered statisti-
cally significant at the level of P < 0.05. In the univariate
analysis, the variables analyzed included age (63 > vs.
≤ 63), T category (T1 vs. T2), overall treatment time
(> 49 vs. ≤ 49), and chemotherapy (combined. vs. not
combined).
Follow-up
After RT alone or combined with chemotherapy, the
patients were evaluated at 1-month intervals for the first
year, at 2-month intervals during the second year, every
3 months during the third year, every 4 months during
the fourth year, and every 6 months thereafter. The
patients who presented with recurrence of disease in the
follow-up time submitted to salvage treatment by total
or partial laryngectomy. The interval time between these
events was recorded.
Results
Local control and patterns of failure
For all 58 patients, the 5-year LC rate was 84.3%. The 5-
year LC rates for T1a, Tb, and T2 were 85.9%, 83%, and
85%, respectively. The difference between the sub-stage
LC rates was not statistically significant.
Of the 58 patients, eight developed recurrent disease
at the primary site, and one had lymph node recur-
rences on the neck. In three of the eight patients, tumor
responses were very poor. The therapies of these three
patients were discontinued at 18 Gy (bulky T1b), 36 Gy
(T2), and 52 Gy (T2), and the patients underwent partial
laryngectomy. Four of five patients with local recurrence
submitted to salvage surgery; one refused surgery. Thus,
only one case was uncontrolled. In the final analysis, the
total laryngectomy-free survival rate was 93% at 5 years,
and the ultimate LC rates for T1a, Tb, and T2 were
100%, 90.9%, and 95.2%, respectively (Table 4).
Overall survival (OS) and cause-specific survival (CSS)
rates
The 5-year OS rate for all patients was 88.1%, and the
5-year OS rates for T1a, Tb, and T2 were 91.6%, 77.8%,
and 89.9% respectively. The 5-year CSS rate in the 58
patients was 95.8%, and the5 - y e a rC S Sr a t e sf o rT 1 a ,
Tb, and T2 were 100%, 87.5%, and 95.2%, respectively
(Table 4).
Univariate analysis
The variables analyzed in 55 patients included age,
T category, overall treatment time, and chemotherapy
f o rL C( T a b l e5 ) .R e s u l t so fu n i v a r i a t ea n a l y s i ss h o w e d
no statistical significance for any of the variables.
Complications
There were no severe acute complications. No late com-
plications such as chondronecrosis were seen, and no
patients required hospitalization due to complications.
Second primary cancers
Twelve of the 58 patients (20%) had second primary
cancers, and two patients (3%) had third cancers. More-
over, 75% of the second lesions were in the upper aero-
digestive tract. Second and third primary sites are
shown in Table 6. There were five cancers diagnosed
synchronously with glottic cancer. The 5-year survival
rate in 12 patients with double primary cancers was
74.0%, and that in 46 patients without double or triple
cancers was 92.5% (p = 0.18).
Discussion
T h eg o a l so ft r e a t m e n tf o re a r l yG Ci n c l u d ec u r ea n d
laryngeal voice preservation.
In this study, the 5-year LC rate for all patients was
84.3%, and the 5-year LC rates for T1a, Tb, and T2
were 85.9%, 83%, and 85%, respectively. The difference
between the sub-stage LC rates was not statistically
Table 4 Local control rate and survival according to the T
stage
T1a T1b T2
5-year local control rates without surgery 85.9% 83% 85.1%
5-year local control rates after surgery 100% 90.9% 95.2%
5-year Overall survival 91.6% 77.8% 89.9%
5-year Cause-specific survival 100% 87.5% 95.2%
Table 5 Univariate Analysis (in 55 patients)
parameter 5-year local control rate(%) P-value
Stage
T1N0 (n = 36) 86.8 0.51
T2N0 (n = 19) 94.1
Overall treatment times
> 49 days (n = 27) 91.4 0.88
≤ 49 days (n = 28) 87.7
Chemotherapy
combined (n = 17) 93.7 0.52
none (n = 38) 86.5
Age
> 63 y.o. (n = 27) 92.5 0.75
≤ 63 y.o. (n = 28) 86.1
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outcome of LC for T2 GC was better than our previous
results (1990-1997) as mentioned in introduction, how-
ever, in the univariate analysis for combined chemother-
apy for LC, the difference had no statistical significance
(p = 0.52). The 5-year LC rate with chemoradiation was
93.7% (Table 5).
According to recently published guidelines [1,2] for
head and neck cancer treatment, all patients with T1-T2
laryngeal cancer should be treated, at least initially, with
the intent of larynx preservation. Chemoradiotherapy is
not recommended for early GC. However, several ana-
lyses of the risk of local failure after RT for early GC
have shown the probability of success to be closely
related to the volume or bulk of the lesion [9-11]. More-
over, recent studies have shown an improvement in LC
for patients with T1 and T2 GC when total radiation is
delivered in a shorter overall treatment time with a
high-dose fractionation [4,12] or hyperfractionation
schedule [13-15]. Therefore, we treated several cases on
a hyperfractionation schedule during the early period of
this analysis.
In contrast, several other reports [16-20] have indicated
that chemoradiation for T2GC is promising and that LC
rates are higher than those for RT alone in Japan.
Therefore, we conducted chemoradiation for bulky T1
and T2 GC with the intent to improve LC. The 5-year
LC rate with chemoradiation was 93.7%. The result was
favorable, but the difference had no statistical
significance.
Our study had several limitations. First, we were
unable to determine the best combination of therapies
using anticancer drugs because this study was not pro-
spective and various chemotherapy regimens were used
at different times. Second, therapies of three patients
were discontinued due to poor responses, and these
cases were counted as recurrences in the statistical ana-
lyses. Two patients, one with a bulky T1b tumor and
the other with an unfavorable T2 tumor, responded
poorly in spite of chemoradiation with low-dose CDDP
and 5-FU. Perhaps bulky tumors and unfavorable T2
tumors require more intensive and powerful anticancer
drugs. Because many regimens of chemotherapy were
used in the cases presented in this study, consideration
must be made of the choice of anticancer drugs, and a
prospective trial must be conducted in which chemora-
d i a t i o ni su s e do na no p t i m a ld o s i n gs c h e d u l ef o rT 1
bulky or T2 GC. A phase II study of chemoradiotherapy
with S-1(per oral anti-cancer drug) for T2GC is cur-
rently underway.
Many recent studies have suggested novel markers of
radiosensitivity, such as DNA ploidy [21], expression of
epidermal growth factor [22], p53 [22,23], Bcl-2 [24],
and microvessel density [25]. Regarding microvessel
density, the biological effects of ionizing radiation are
critically dependent on the existence of oxygen in tis-
sues, which may be another reason for the poor
responses. The cases of poor response are considered to
involve radioresistant tumors, said to account for 6-30%
of all tumors [25]. If poor responses to radiotherapy
with or without chemotherapy can be predicted, surgery
or another procedure may be selected.
In the present study, a second malignancy occurred in
more than 20% of the cases, 75% of which were in the
upper aerodigestive tract. Additionally, the prognoses
for patients with a second malignancy were poorer than
those of patients with a single malignancy, though the
difference was not statistically significant.
After treatment is completed, regular check-ups are
very important, and long-term follow-up is required
[26,27].
Conclusions
By means of radiotherapy with or without chemother-
apy, we achieved a high rate of LC in patients with T1-
T2 GC. Although the combination therapy yielded the
most favorable results, there was no statistical difference
in the LC rates.
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Table 6 Incidence of secondary primary cancers in this
study
Primary site number percentage
thyroid 2 15
oropharynx 1 7.7
hypopharynx 1 7.7
esophagus 2 15
stomach 2 15
lung 3 20
liver 1 7.7
colon 3 20
Total 15 100
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